COR
$325.37-1.40%
as of close, Oct 27, 2026
☾ AH $325.37 -1.40%
COR — Cencora Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeEEEEEEEEEEEEEE
100.0150.0200.0250.0300.0350.0020.0M$325.37—20162019202120242026
2026-10-27
Price$325.37
MA20$304.84
MA50$321.12
Vol4.5M
Key stats#
Price data
- Price
- $325.37
- YTD price return
- -3.67%
- YTD total return
- -3.09%
- Next earnings
- Nov 4, 2026 · Before open
- Market cap
- 62.1B
- Enterprise value
- 72.9B
- Shares outstanding
- 190.8M
- 52W low
- $244.82
- 52W high
- $377.54
- From 52W high
- -13.82%
- From 52W low
- +32.90%
- 52W range
- 61%
- Beta
- 0.57
Volume
- Rel volume
- 0.89×
- 30D volume
- 1.3M
- 30D $ vol
- 401.8M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- −$299K
- Insider net 3M
- −$4.7M
- Insider net 1Y
- −$6.0M
Form 4 transactions by trade date, as filed; latest on file 2026-10-01.
Fundamentals
- Sales (ttm)
- 332.8B
- Sales/share
- $1,743.84
- EPS (ttm)
- $13.46
- FCF (ttm)
- 4.1B
- FCF/share
- $21.28
- Book value/share
- $15.99
- Net margin
- 0.79%
- ROE
- 86.03%
- ROA
- 3.13%
- Debt / equity
- 3.75×
- Current ratio
- 0.93
Growth (CAGR, ttm) · 10Y
- Sales
- +5.09%+9.36%+10.25%+8.68%
- Net income
- +38.38%+15.82%n/a+4.78%
- FCF
- +255.96%+13.28%+9.63%+4.55%
- Shares
- -1.57%-1.91%-1.69%-1.17%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- +39.01%+18.00%n/a+6.40%
- Sales/share
- +6.77%+11.48%+12.14%+9.97%
- FCF/share
- +261.66%+15.49%+11.51%+5.79%
- Book value/share
- +56.58%+67.63%+144.61%+6.21%
- Dividend/share
- +8.80%+7.06%+6.20%+6.02%
- Price
- -3.18%+20.13%+22.17%+15.15%
- Total return
- -2.44%+21.14%+23.67%+17.69%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 24.2×
- P/OI (ttm)
- 20.4×
- Fwd P/E
- 16.7×
- P/S (ttm)
- 0.2×
- P/B (mrq)
- 20.4×
- P/FCF (ttm)
- 15.3×
- EV/EBITDA (fy)
- 17.9×
- EV/Sales (ttm)
- 0.2×
- FCF yield (ttm)
- 6.54%
- Dividend yield (fwd)
- 0.74%
- Dividend yield (ttm)
- 0.74%
- Dividend/share (fwd)
- $2.40
- Buyback yield (realized, 1y)
- 1.57%
- Shareholder yield (realized, 1y)
- 2.38%
- Buyback yield (cash, ttm)
- 1.61%
- Shareholder yield (cash, ttm)
- 2.36%
Vs own 10Y history
- P/E
- 68th
- P/OI
- 80th
- P/S
- 94th
- P/B
- 51st
- P/FCF
- 65th
Bar = where today’s multiple sits in COR’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-27#
1D
-1.40%
5D
-5.21%
1M
+6.01%
3M
+4.57%
YTD
-3.67%
1Y
-3.18%
5Y
+172.16%
Recent filings#
- Oct 218-K · CENCORA TO ACQUIRE AMERICAN ONCOLOGY NETWORK TO STRENGTHEN SUPPORT OF COMMUNITY ONCOLOGY
- Sep 258-K · CENCORA ELECTS ROBERT E. SANCHEZ TO ITS BOARD OF DIRECTORS
- Sep 16Insider sale · GREENBERG LON R (Director) sold 1,280 shares for $411K at $321.30
- Aug 24Insider sale · Campbell Elizabeth S (Executive Vice President) sold 11,300.471 shares for $3.7M at $324.12
- Aug 5Earnings · Earnings release — EPS $4.48 vs $4.37 est. (+2.5%); revenue $84.75B (+5% y/y) 3.6%
Financial statements
Open full COR financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +8.32% | +0.22% |
| JNJ | Johnson & Johnson | -0.92% | +0.91% |
| ABBV | AbbVie Inc. | +8.34% | -0.12% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +8.98% | -0.08% |
| MRK | Merck & Co. Inc. | -4.68% | +0.86% |
| NVS | Novartis AG | +7.84% | +1.98% |
| TMO | Thermo Fisher Scientific Inc. | +2.67% | +1.19% |
| AMGN | Amgen Inc. | +8.04% | +0.75% |
